Renal angiomyoadenomatous tumour: Imaging features

Sahni, V. Anik; Hirsch, Michelle S.; Silverman, Stuart G.

doi:10.5489/cuaj.303

Cited by 7 publications

(3 citation statements)

References 17 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, if CCPRCT can be predicted in advance, not only partial nephrectomy but also minimally invasive treatment such as ablation or active surveillance can be considered as treatment options. However, it is not easy to clearly distinguish between CCPRCT and small renal mass with the other histologic subtype on CT or magnetic resonance imaging [ 18 ]. If there is no significant change in the image during the follow-up period, it would be a good strategy to establish a treatment plan after confirming the pathology through a biopsy [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical features and Surgical Outcome of Clear Cell Papillary Renal Cell Tumor: result from a prospective cohort

et al. 2023

View full text Add to dashboard Cite

Background Clear cell papillary renal cell tumor (CCPRCT) was first reported in 2006 a patient with end stage renal disease. After that it was discovered in the kidney without end stage renal disease in the 2010s and started to be mentioned in pathology and urology. The incidence of CCPRCT is low and most of it is discovered incidentally, so there is a lack of reports on clinical characteristics and surgical outcome. Methods This study used clinical data from the Seoul National University Prospectively Enrolled Registry for Renal Cell Carcinoma-Nephrectomy (SUPER-RCC-Nx). Between August 2016 and July 2022, patients who underwent radical or partial nephrectomy with clear cell papillary RCC with pathological finding were included in this study. All patients’ pathologic reports were reviewed by 1 pathologist. Clinical characteristics and surgical outcomes were presented through descriptive statistics, and Kaplan-Meier curve used for survival analysis. Results Of the 2057 patients, CCPRCT was reported in 36 patients (1.8%). The median follow up period was 26.8 months. The median age was 67 years, and there were 10 females and 26 males. The median tumor size was 1.2 cm. Twenty-nine patients underwent partial nephrectomy. Seven patients with end-stage renal disease underwent radical nephrectomy. The median operative time for patients who underwent partial nephrectomy was 97.5 min and the estimated blood loss was 100 cc. The median hospital days was 4 and 30-day complications were 2 cases with clavien-dindo classification III or higher. During the follow-up period, there was no recurrence and cancer specific mortality. Conclusions The size of CCPRCT was small and there was no advanced stage at that time of diagnosis. There was no recurrence or cancer specific mortality during the follow-up period. A multi-center study with a large scale is needed in the future. Trial registration Seoul National University Hospital (SNUH) Institutional Review Board (IRB) (approval number: 2210-126-1371).

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical features and Surgical Outcome of Clear Cell Papillary Renal Cell Tumor: result from a prospective cohort

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Epithelial, and vascular components are intermingled in such a way that a fine labyrinth of capillaries will rim the epithelial component [4] which is seen more clearly in immunostaining for endothelial cells (CD 31 or CD 34). [2][3][4] Such a vascular pattern with capillary-sized vessels were seen in this case which were highlighted by CD 34 immunostaining. This labyrinthine capillary network in close contact with the epithelial component is a characteristic feature described in RAT.…”

Section: Discussionmentioning

confidence: 99%

“…[3] It presents clinically as a renal mass and is seen as a well marginated solid, contrast material -enhanced renal tumor in imaging studies. [4] We are reporting our case of renal angiomyoadenomatous tumour to be added to the database of these tumours.…”

Section: Introductionmentioning

confidence: 99%

Renal angiomyoadenomatous tumour

Jayalakshmy

Jose

Feroze

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Renal angiomyoadenomatous tumour is a newly described rare neoplasm. This tumour is characterised microscopically by admixture of three components-epithelial cells arranged in tubules and nests, angiomyomatous stroma and capillary sized interconnecting vascular channels in close association with the epithelial cell clusters. Microscopically it has wide range of differential diagnoses which include mixed epithelial and stromal tumour of kidney, angiomyolipoma and clear cell renal cell carcinoma with angiomyolipomatous/ angiomyoadenomatous areas. Renal angiomyoadenomatous tumour should be differentiated from these tumours. Till now, only 10 cases have been reported in English medical literature. Here, we are reporting a case of renal angiomyoadenomatous tumour in a 29 year-old female patient who presented with hematuria and low backache and describing its main features so as to differentiate this entity from other renal tumours. To the best of our knowledge, this is the first case to be reported from India.

show abstract

Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex

et al. 2018

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) with angioleiomyoma-like stroma appears to be molecularly distinct from clear cell RCC; however, its relationship to clear cell papillary RCC remains debated. Recent studies have found that similar tumors sometimes occur in patients with tuberous sclerosis complex (TSC), of which 1 study found unexpectedly negative succinate dehydrogenase B (SDHB) immunostaining. We evaluated immunohistochemistry for SDHB in 12 apparently sporadic RCCs with angioleiomyoma-like stroma and correlated with clinical information for stigmata of TSC. Tumors were compared with a group of 16 clear cell papillary RCCs and 6 unclassified tumors with prominent stroma. With the exception of 1 unclassified tumor, all exhibited at least focal cytoplasmic staining for SDHB protein, often requiring high magnification and better appreciated with increased antibody concentration. Detailed history information was available for 9 of 11 patients with smooth muscle-rich tumors, revealing no stigmata of undiagnosed TSC. Electron microscopy performed on 1 of these tumors revealed mitochondria to be very sparse, potentially accounting for the weak immunohistochemical labeling for SDHB protein. Weak SDHB immunostaining may represent another shared feature of RCC with angioleiomyoma-like stroma and clear cell papillary RCC, likely due to sparse mitochondria, strengthening the possible relationship of these entities. Although smooth muscle-rich tumors have been recently reported in patients with TSC, absence of staining in tumors with this pattern may not be specific for TSC. In tumors with pale or clear cytoplasm, immunohistochemical staining for SDHB should be interpreted with caution as evidence of abnormality in the SDH pathway.

show abstract

Renal angiomyoadenomatous tumour: Imaging features

Cited by 7 publications

References 17 publications

Clinical features and Surgical Outcome of Clear Cell Papillary Renal Cell Tumor: result from a prospective cohort

Clinical features and Surgical Outcome of Clear Cell Papillary Renal Cell Tumor: result from a prospective cohort

Renal angiomyoadenomatous tumour

Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex

Contact Info

Product

Resources

About